Clinical trial · Interventional
Prognostic Utility of the Imaging and Biological Signatures in Nasopharyngeal Carcinoma
Integrating Biomarkers From Serum/Plasma and Molecular Images to Predict Occult Distant Metastases in Nasopharyngeal Carcinoma Patients With M0 Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nasopharyngeal carcinoma (NPC) differs from other head and neck malignancies terms of its epidemiology, pathology, and treatment outcome. Although NPC is a radiosensitive tumor, distant recurrence remains a clinical challenge. Therefore, the investigators conducted this study to prospectively investigate the role of imaging and blood biomarkers in predicting the prognosis of NPC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-FDG PET/CT, MRI | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 18F-FDG PET/CT with MRI and blood sampling
- description
- The enrolled subjects received 18F-FDG PET/CT and MRI before, during, and after the primary definitive treatment. The blood sample was collected on the same day of PET/CT scan.
- interventionNames
- Device: 18F-FDG PET/CT, MRI
Primary outcomes (1)
- measure
- Recurrence-free survival
- timeFrame
- 5 years
- description
- The time between the end of chemoradiotherapy and the date of recurrence or censored at the date of the last follow-up
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy proved primary M0 nasopharyngeal carcinoma Exclusion Criteria: * Woman with pregnancy or during lactation * A history of other malignancies or presence of recurrent tumors * A serum glucose level \> 200mg/dL before PET scan
References
Publications (0)
Data not yet available